Literature DB >> 16437620

Extraintestinal manifestations in inflammatory bowel disease.

Silvio Danese1, Stefano Semeraro, Alfredo Papa, Italia Roberto, Franco Scaldaferri, Giuseppe Fedeli, Giovanni Gasbarrini, Antonio Gasbarrini.   

Abstract

Inflammatory bowel diseases (IBD) can be really considered to be systemic diseases since they are often associated with extraintestinal manifestations, complications, and other autoimmune disorders. Indeed, physicians who care for patients with ulcerative colitis and Crohn's disease, the two major forms of IBD, face a new clinical challenge every day, worsened by the very frequent rate of extraintestinal complications. The goal of this review is to provide an overview and an update on the extraintestinal complications occurring in IBD. Indeed, this paper highlights how virtually almost every organ system can be involved, principally eyes, skin, joints, kidneys, liver and biliary tracts, and vasculature (or vascular system) are the most common sites of systemic IBD and their involvement is dependent on different mechanisms.

Entities:  

Mesh:

Year:  2005        PMID: 16437620      PMCID: PMC4725142          DOI: 10.3748/wjg.v11.i46.7227

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  117 in total

Review 1.  Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.

Authors:  William J Sandborn; Stephen B Hanauer
Journal:  Am J Gastroenterol       Date:  2002-12       Impact factor: 10.864

2.  Sweet syndrome.

Authors:  Lawrence E Gibson
Journal:  Mayo Clin Proc       Date:  2005-04       Impact factor: 7.616

3.  Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.

Authors:  K M Boberg; A Bergquist; S Mitchell; A Pares; F Rosina; U Broomé; R Chapman; O Fausa; T Egeland; G Rocca; E Schrumpf
Journal:  Scand J Gastroenterol       Date:  2002-10       Impact factor: 2.423

4.  Fracture risk is increased in Crohn's disease, but not in ulcerative colitis.

Authors:  P Vestergaard; K Krogh; L Rejnmark; S Laurberg; L Mosekilde
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

5.  Pleuropericarditis and disseminated intravascular coagulation in ulcerative colitis.

Authors:  S Orii; T Chiba; I Nakadate; T Fujiwara; N Ito; M Ishii; S Oana; T Chida; N Kudara; T Terui; T Yamaguchi; K Suzuki
Journal:  J Clin Gastroenterol       Date:  2001-03       Impact factor: 3.062

6.  Inflammatory bowel disease promotes venous thrombosis earlier in life.

Authors:  O Grip; P J Svensson; S Lindgren
Journal:  Scand J Gastroenterol       Date:  2000-06       Impact factor: 2.423

7.  Venous thromboembolism in inflammatory bowel disease.

Authors:  Craig A Solem; Edward V Loftus; William J Tremaine; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2004-01       Impact factor: 10.864

8.  Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?

Authors:  W Miehsler; W Reinisch; E Valic; W Osterode; W Tillinger; T Feichtenschlager; J Grisar; K Machold; S Scholz; H Vogelsang; G Novacek
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

9.  Interferon-gamma exerts its negative regulatory effect primarily on the earliest stages of murine erythroid progenitor cell development.

Authors:  C Q Wang; K B Udupa; D A Lipschitz
Journal:  J Cell Physiol       Date:  1995-01       Impact factor: 6.384

10.  The association between corticosteroid use and development of fractures among IBD patients in a population-based database.

Authors:  Charles N Bernstein; James F Blanchard; Colleen Metge; Marina Yogendran
Journal:  Am J Gastroenterol       Date:  2003-08       Impact factor: 10.864

View more
  90 in total

1.  Protective effect of aqueous extract of Spinacia oleracea leaves in experimental paradigms of inflammatory bowel disease.

Authors:  Kishor Vasant Otari; Priyanka Subhash Gaikwad; Rajkumar Virbhadrappa Shete; Chandrashekhar Devidas Upasani
Journal:  Inflammopharmacology       Date:  2012-01-11       Impact factor: 4.473

2.  Mesalamine-induced Pneumonitis and Serum Sickness-like Reaction.

Authors:  Adam Harris; Shanti Eswaran; Brian Bosworth; Maya Gambarin-Gelwan; Ellen J Scherl
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-11

3.  Smoking is Associated With Extra-intestinal Manifestations in Inflammatory Bowel Disease.

Authors:  M Severs; S J H van Erp; M E van der Valk; M J J Mangen; H H Fidder; M van der Have; A A van Bodegraven; D J de Jong; C J van der Woude; M J L Romberg-Camps; C H M Clemens; J M Jansen; P C van de Meeberg; N Mahmmod; C Y Ponsioen; C Bolwerk; J R Vermeijden; M J Pierik; P D Siersema; M Leenders; A E van der Meulen-de Jong; G Dijkstra; B Oldenburg
Journal:  J Crohns Colitis       Date:  2015-12-30       Impact factor: 9.071

4.  Oral Manifestations of Inflammatory Bowel Diseases: Two Case Reports.

Authors:  Manoela Seadi Pereira; Maria Cristina Munerato
Journal:  Clin Med Res       Date:  2016-02-10

Review 5.  Oral pathology in inflammatory bowel disease.

Authors:  Miranda Muhvić-Urek; Marija Tomac-Stojmenović; Brankica Mijandrušić-Sinčić
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

6.  Platelet activation and platelet-leukocyte aggregation elicited in experimental colitis are mediated by interleukin-6.

Authors:  Serena L S Yan; Janice Russell; D Neil Granger
Journal:  Inflamm Bowel Dis       Date:  2014-02       Impact factor: 5.325

Review 7.  Extraintestinal manifestations and complications in IBD.

Authors:  Claudia Ott; Jürgen Schölmerich
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-09       Impact factor: 46.802

8.  Decreased retinal blood flow in experimental colitis; improvement by eye drop administration of losartan.

Authors:  Megan N Watts; Randa S Eshaq; Patsy R Carter; Norman R Harris
Journal:  Exp Eye Res       Date:  2013-07-02       Impact factor: 3.467

Review 9.  Biological therapy for dermatological manifestations of inflammatory bowel disease.

Authors:  Maddalena Zippi; Roberta Pica; Daniela De Nitto; Paolo Paoluzi
Journal:  World J Clin Cases       Date:  2013-05-16       Impact factor: 1.337

10.  Trends in pediatric urolithiasis: patient characteristics, associated diagnoses, and financial burden.

Authors:  Kirsten Kusumi; Brian Becknell; Andrew Schwaderer
Journal:  Pediatr Nephrol       Date:  2014-12-07       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.